OncoMatch

OncoMatch/Clinical Trials/NCT06429098

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Is NCT06429098 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and azacitidine for acute myeloid leukemia.

Phase 2RecruitingThe First Affiliated Hospital of Soochow UniversityNCT06429098Data as of May 2026

Treatment: Venetoclax · azacitidine · decitabine · Cytarabine — This investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly diagnosed CBFβ::MYH11-positive acute myeloid leukemia.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Biomarker criteria

Required: CBFB cbfβ::myh11 fusion

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: hypomethylating agent

Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count

Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)

Cannot have received: chemotherapeutic agent

Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count

Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)

Cannot have received: targeted drug therapy

Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count

Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify